Fidaxomicin & Clostridioides difficile infection (CDI) (recurrent)

Regulatory status

Fidaxomicin is approved by both the FDA and EMA for the treatment of Clostridioides difficile infection (CDI), including recurrent cases. The drug is recommended in several guidelines as first-line therapy for Clostridioides difficile infection (CDI) (initial) and Clostridioides difficile infection (CDI) (recurrent) due to its reduced risk of recurrence compared to vancomycin, and is broadly used in both adults and pediatric populations
Lee et al. 2023 Open Forum Infectious Diseases 10(Suppl_2): ofad500.754
Normington et al. 2024 Curr Opin Gastroenterol 40(1): 7-13

Clinical data

Fidaxomicin is the preferred agent for treatment of the first recurrence of CDI when available and feasible
van Prehn et al. 2021 Clin Microbiol Infect 27 (suppl 2): S1-21

While fidaxomicin is effective at killing the C difficile bacteria in its vegetative form, they do not restore the disrupted microbiome
Theriot & Young 2015 Annu Rev Microbiol 69(1): 445-461
Smits et al. 2016 Nat Rev Dis Primers 2(1): 16020
Thorpe et al. 2018 PLoS One 13(8): e0199810

see also:
Antibiotics & Clostridioides difficile infection (CDI) (recurrent)
Clostridioides difficile infection (CDI) (recurrent) & Drugs/Treatments
Fidaxomicin & Clostridioides difficile infection (CDI) (initial)
Fidaxomicin + Vancomycin & Clostridioides difficile infection (CDI) (recurrent)